EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-world anti-EGFR rechallenge in circulating tumor DNA-profiled metastatic colorectal cancer: the REalCHALLENGE study

Gianluca Mauri, Laura Roazzi, Nadia Saoudi González, Paolo Ciracì, Manuel Pedregal-Trujillo, Valentino Martelli, Angelo Dipasquale, Carmen Belli, Federica Tosi, Davide Bernasconi, Giuseppe Sala, Elena Tamborino und 18 weitere

European Journal of Cancer · 2026-11 · 118182

DOI: 10.1016/j.ejca.2026.118182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Gianluca Mauri und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology, and Molecular Medicine, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Niguarda Oncology Foundation ETS, AIRC Foundation for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-epidermal growth factor receptor (EGFR) rechallenge is a standard therapeutic option for patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who benefited from prior anti-EGFR-based regimens. Circulating tumor DNA (ctDNA)-guided molecular selection improved efficacy, but routine testing and real-world evidence remain limited.

Methods

REalCHALLENGE is a retrospective study aiming at assessing the activity of real-world anti-EGFR rechallenge versus other standard-of-care (SoC) treatments in microsatellite stable (MSS), RAS/BRAF WT mCRC patients profiled by ctDNA. The primary endpoint was overall response rate (ORR), while secondary endpoints included disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Hyperselection integrating archival solid tissue profiling to ctDNA profiling was also investigated.

Results

104 patients were included: 69 (66%) ctDNA RAS/BRAF WT and 35 (34%) mutants. Among ctDNA WT, anti-EGFR rechallenge led to higher ORR compared with SoC (29% vs 0%, p=0.003), and DCR (68% vs 42%, p=0.049). A trend toward longer median PFS was observed (4.7 vs 2.9 months, p=0.06), alongside with improved OS (21.9 vs 11.1 months, p=0.04). In ctDNA mutant patients, outcomes were comparable between groups. In hyperselected non-mutant patients, anti-EGFR rechallenge led to improved ORR (34.4% vs 0%; p=0.006), PFS (4.98 vs 2.59 months; p=0.02) and OS (22.20 vs 11.18 months; p=0.02). No new safety signals emerged.

Conclusions

Anti-EGFR rechallenge confirmed meaningful activity in ctDNA RAS/BRAF WT mCRC patients in a real-world setting, particularly in a hyperselected population integrating ctDNA and tissue NGS. These findings support the value of molecular profiling to optimize selection for anti-EGFR rechallenge.

Schlagwörter

Stichwörter der Autor:innen

Anti-EGFRCetuximabColon and rectal cancerLiquid biopsyPanitumumabReintroduction

Autor:innen und Institutionen

  • Department of Hematology, Oncology, and Molecular Medicine, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Department of Hematology, Oncology, and Molecular Medicine, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Department of Oncology and Hemato‑Oncology, Università degli Studi di Milano, Mil…
  • Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.
  • Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • START Madrid-Fundación Jiménez Díaz (FJD) Early Phase Program, Fundación Jiménez Díaz Hospital, Madrid, Spain.
  • Medical Oncology, AOM IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Förderung

  • Niguarda Oncology Foundation ETS
  • AIRC Foundation for Cancer Research

Zitieren

APA

Mauri, G., Roazzi, L., Saoudi González, N., Ciracì, P., Pedregal-Trujillo, M., Martelli, V., Dipasquale, A., Belli, C., Tosi, F., Bernasconi, D., Sala, G., Tamborino, E., Bonazzina, E. F., Galli, E., Monti, L., Ghezzi, S., Salvà, F., Pasquinucci, V., Rueda-Lara, A., …, & Sartore-Bianchi, A. (2026). Real-world anti-EGFR rechallenge in circulating tumor DNA-profiled metastatic colorectal cancer: the REalCHALLENGE study. European Journal of Cancer, 118182. https://doi.org/10.1016/j.ejca.2026.118182

Vancouver

Mauri G, Roazzi L, Saoudi González N, Ciracì P, Pedregal-Trujillo M, Martelli V, et al. Real-world anti-EGFR rechallenge in circulating tumor DNA-profiled metastatic colorectal cancer: the REalCHALLENGE study. European Journal of Cancer. 2026:118182. doi:10.1016/j.ejca.2026.118182

BibTeX
@article{Mauri2026,
  author = {Mauri, Gianluca and Roazzi, Laura and Saoudi González, Nadia and Ciracì, Paolo and Pedregal-Trujillo, Manuel and Martelli, Valentino and Dipasquale, Angelo and Belli, Carmen and Tosi, Federica and Bernasconi, Davide and Sala, Giuseppe and Tamborino, Elena and Bonazzina, Erica Francesca and Galli, Edoardogregorio and Monti, Letizia and Ghezzi, Silvia and Salvà, Francesc and Pasquinucci, Valentino and Rueda-Lara, Antonio and Gattolin, Margherita and Puccini, Alberto and Ciardiello, Davide and Curigliano, Giuseppe and Simonelli, Matteo and Pastorino, Alessandro and Doger, Bernard and Cremolini, Chiara and Elez, Elena and Siena, Salvatore and Sartore-Bianchi, Andrea},
  title = {Real-world anti-EGFR rechallenge in circulating tumor DNA-profiled metastatic colorectal cancer: the REalCHALLENGE study},
  journal = {European Journal of Cancer},
  year = {2026},
  pages = {118182},
  doi = {10.1016/j.ejca.2026.118182}
}
Kostenlos starten →